|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.039 SGD | -2.50% |
|
0.00% | -13.33% |
| 03-12 | Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer | MT |
| 03-12 | IX Biopharma Introduces New Sublingual Wafer | MT |
iX Biopharma Ltd. reported earnings results for the full year ended June 30, 2022. For the full year, the company reported sales was SGD 14.39 million compared to SGD 1.75 million a year ago. Net loss was SGD 4.6 million compared to SGD 8.23 million a year ago.
Basic loss per share from continuing operations was SGD 0.0062. Diluted loss per share from continuing operations was SGD 0.0062.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.33% | 22.2M | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
IX BIOPHARMA LTD. 
